KIN FONG HONG

Dr. KIN FONG HONG

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CZChuyun Zhao
Chuyun Zhao
WLWenjie Lai
Wenjie Lai
YLYu Li
Yu Li
KHKIN FONG HONG
KIN FONG HONG
Youhua XuYouhua Xu
Youhua Xu
The incidence and mortality of diabetes have increased dramatically in recent decades. New strategies to treat diabetes and its complications with minimal side effects are urgently needed. New monomeric molecules extracted from herbs are an alternative medicine that is being explored as candidate drugs for the treatment of diabetes and its complications. Nobiletin, a citrus flavonoid, has recently received increasing attention in scientific research due to its properties in combating diabetes and its complications, while existing research is scattered and unsystematic. This article summarizes recent studies and reviews the potential therapeutic role of nobiletin in preventing and alleviating diabetes and its complications, aiming to provide promising strategies for the clinical management of diabetes and its complications.

1 January 2024 in Journal of Integrative and Complementary Medicine
Verified
Journal Article
Closed access
KHKIN FONG HONG
KIN FONG HONG
PLPei-Yu Liu
Pei-Yu Liu
WZWei Zhang
Wei Zhang
DGDing-Kun Gui
Ding-Kun Gui
Youhua XuYouhua Xu
Youhua Xu
Objective: This meta-analysis evaluated the beneficial and potential adverse effects of Astragalus in the treatment of patients with type 2 diabetes mellitus (T2DM). Methods: The authors searched for randomized controlled trials of Astragalus treatment for patients with T2DM in the following databases: PubMed, Embase, Cochrane Library, China Knowledge Resource Integrated Database (CNKI), Wanfang Data, China Science and Technology Journal Database (CQVIP), and SinoMed. Two reviewers conducted independent selection of studies, data extraction, and coding, as well as the assessment of risk of bias in the studies included. Standard meta-analysis and, if appropriate, meta-regression were performed using the STATA, v.15.1, software. Results: This meta-analysis encompasses 20 studies and a total of 953 participants. Compared to the control group (CG), the observation group (OG) decreased fasting plasma glucose (FPG) (WMD = −0.67, 95% CI: −1.13∼−0.20, P = 0.005), 2 hours postprandial plasma glucose (2hPG) (WMD = −0.67 (95% CI: −1.13∼−0.20, P=0.005), glycated hemoglobin A1C (HbA1c) (WMD = −0.93, 95% CI: −1.22∼−0.64, P = 0.000), homeostatic model assessment for insulin resistance (HOMA-IR) (WMD = −0.45, 95% CI: −0.99∼0.99, P = 0.104), insulin sensitive index (WMD = 0.42, 95% CI: 0.13-0.72, P = 0.004). The total effective ratio of the OG is more effective than CG (RR = 1.33, 95% CI: 1.26-1.40, P = 0.000), the significant effective ratio (RR = 1.69, 95% CI: 1.48-1.93, P = 0.000). Conclusions: Astragalus may provide specific benefits for T2DM patients as an adjuvant treatment. Nonetheless, the certainty of the evidence and risk of bias fell short of optimal performance, indicating the need for additional clinical research to ascertain potential effects. PROSPERO REGISTRATION NUMBER CRD42022338491.